Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

PURPOSE: The CLEOPATRA (Clinical Evaluation of Trastuzumab and Pertuzumab) study demonstrated superior progression-free survival (PFS) and overall survival when pertuzumab was added to trastuzumab and docetaxel. Paclitaxel given once per week is effective and less toxic than docetaxel. We performed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Dang, Chau, Iyengar, Neil, Datko, Farrah, D'Andrea, Gabriella, Theodoulou, Maria, Dickler, Maura, Goldfarb, Shari, Lake, Diana, Fasano, Julie, Fornier, Monica, Gilewski, Theresa, Modi, Shanu, Gajria, Devika, Moynahan, Mary Ellen, Hamilton, Nicola, Patil, Sujata, Jochelson, Maxine, Norton, Larry, Baselga, José, Hudis, Clifford
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2015
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5747317/
https://ncbi.nlm.nih.gov/pubmed/25547504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.1745
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi